109,400 Shares in Vera Therapeutics, Inc. (NASDAQ:VERA) Bought by Springhill Fund Asset Management HK Co Ltd

Springhill Fund Asset Management HK Co Ltd purchased a new position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 109,400 shares of the company's stock, valued at approximately $4,627,000. Vera Therapeutics makes up approximately 7.5% of Springhill Fund Asset Management HK Co Ltd's portfolio, making the stock its 6th largest position. Springhill Fund Asset Management HK Co Ltd owned approximately 0.17% of Vera Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Huntington National Bank acquired a new stake in shares of Vera Therapeutics in the fourth quarter valued at approximately $26,000. AlphaQuest LLC acquired a new position in shares of Vera Therapeutics in the 4th quarter worth approximately $34,000. KBC Group NV raised its holdings in shares of Vera Therapeutics by 127.2% in the 4th quarter. KBC Group NV now owns 2,477 shares of the company's stock worth $105,000 after purchasing an additional 1,387 shares in the last quarter. Moors & Cabot Inc. acquired a new stake in Vera Therapeutics during the fourth quarter valued at approximately $220,000. Finally, E Fund Management Co. Ltd. boosted its holdings in Vera Therapeutics by 22.3% during the fourth quarter. E Fund Management Co. Ltd. now owns 6,203 shares of the company's stock worth $262,000 after buying an additional 1,130 shares in the last quarter. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Vera Therapeutics Stock Up 4.1 %

VERA traded up $0.90 during trading on Friday, hitting $22.71. The company had a trading volume of 237,065 shares, compared to its average volume of 908,483. The firm's 50-day moving average price is $27.89 and its 200 day moving average price is $37.42. The company has a market capitalization of $1.45 billion, a PE ratio of -8.70 and a beta of 1.28. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. Vera Therapeutics, Inc. has a one year low of $18.53 and a one year high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.11. As a group, equities analysts expect that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on VERA shares. Wolfe Research began coverage on Vera Therapeutics in a research report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 price target for the company. Guggenheim increased their price objective on Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. The Goldman Sachs Group initiated coverage on shares of Vera Therapeutics in a research note on Tuesday, January 28th. They issued a "buy" rating and a $58.00 price objective on the stock. Finally, JPMorgan Chase & Co. cut their price target on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a research note on Tuesday, March 4th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $64.67.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.